In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Vir Biotechnology trades 17.9% above its PERT-weighted fair value of $7.99, with significant disparity between highly negative DCF values and optimistic analyst targets ($18-$30). Financial health reveals strong liquidity and leverage but lacks profitability and efficiency, indicating operational challenges. Monte Carlo analysis shows minimal downside risk, suggesting price stability despite valuation concerns.